These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 30458722)

  • 21. Recommendations for driving after implantable cardioverter defibrillator implantation and the use of a wearable cardioverter defibrillator : Different viewpoints around the world.
    Cooper M; Berent T; Auer J; Berent R
    Wien Klin Wochenschr; 2020 Dec; 132(23-24):770-781. PubMed ID: 32435868
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Validation of defibrillator lead performance registry data: insight from the Danish Pacemaker and ICD Register.
    Kristensen AE; Larsen JM; Nielsen JC; Johansen JB; Haarbo J; Petersen HH; Riahi S
    Europace; 2017 Jul; 19(7):1187-1192. PubMed ID: 27738061
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Driving of a motor vehicle after implantation of a cardioverter-defibrillator in malignant heart rhythm disorders. Criteria for the medical assessment of driving fitness in Europe].
    Lüderitz B; Jung W
    Dtsch Med Wochenschr; 1996 Feb; 121(5):119-23. PubMed ID: 8717193
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Decreased Quality of Life Due to Driving Restrictions After Cardioverter Defibrillator Implantation.
    Timmermans I; Jongejan N; Meine M; Doevendans P; Tuinenburg A; Versteeg H
    J Cardiovasc Nurs; 2018; 33(5):474-480. PubMed ID: 29601373
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Propensity score matched comparison of subcutaneous and transvenous implantable cardioverter-defibrillator therapy in the SIMPLE and EFFORTLESS studies.
    Brouwer TF; Knops RE; Kutyifa V; Barr C; Mondésert B; Boersma LVA; Lambiase PD; Wold N; Jones PW; Healey JS
    Europace; 2018 Sep; 20(FI2):f240-f248. PubMed ID: 29771327
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mortality Implications of Appropriate Implantable Cardioverter Defibrillator Therapy in Secondary Prevention Patients: Contrasting Mortality in Primary Prevention Patients From a Prospective Population-Based Registry.
    Almehmadi F; Porta-Sánchez A; Ha ACT; Fischer HD; Wang X; Austin PC; Lee DS; Nanthakumar K
    J Am Heart Assoc; 2017 Aug; 6(8):. PubMed ID: 28862957
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of elapsed time from coronary revascularization to implantation of a cardioverter defibrillator on long-term survival in the MADIT-II trial.
    Barsheshet A; Goldenberg I; Moss AJ; Huang DT; Zareba W; McNitt S; Klein HU; Guetta V
    J Cardiovasc Electrophysiol; 2011 Nov; 22(11):1237-42. PubMed ID: 21615813
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Impact of Chronic Total Coronary Occlusion on Recurrence of Ventricular Arrhythmias in Ischemic Secondary Prevention Implantable Cardioverter-Defibrillator Recipients (VACTO Secondary Study): Insights From Coronary Angiogram and Electrogram Analysis.
    Nombela-Franco L; Iannaccone M; Anguera I; Amat-Santos IJ; Sanchez-Garcia M; Bautista D; Calvelo MN; Di Marco A; Moretti C; Pozzi R; Scaglione M; Cañadas V; Sandin-Fuentes M; Arenal A; Bagur R; Perez-Castellano N; Fernandez-Perez C; Gaita F; Macaya C; Escaned J; Fernández-Lozano I
    JACC Cardiovasc Interv; 2017 May; 10(9):879-888. PubMed ID: 28473110
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Characteristics and early clinical outcomes of patients undergoing totally subcutaneous vs. transvenous single chamber implantable cardioverter defibrillator placement.
    Mithani AA; Kath H; Hunter K; Andriulli J; Ortman M; Field J; Russo AM
    Europace; 2018 Feb; 20(2):308-314. PubMed ID: 28383717
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Implantable Cardioverter Defibrillators for Primary Prevention of Mortality in Patients With Nonischemic Cardiomyopathy: A Meta-Analysis of Randomized Controlled Trials.
    Stavrakis S; Asad Z; Reynolds D
    J Cardiovasc Electrophysiol; 2017 Jun; 28(6):659-665. PubMed ID: 28316104
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The implantable defibrillator and return to operation of vehicles study.
    Mylotte D; Sheahan RG; Nolan PG; Neylon MA; McArdle B; Constant O; Diffley A; Keane D; Nash PJ; Crowley J; Daly K
    Europace; 2013 Feb; 15(2):212-8. PubMed ID: 22968849
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Optimal timing of implantable cardioverter-defibrillator implantation after myocardial infarction: a decision analysis.
    Piccini JP; Al-Khatib SM; Myers ER; Anstrom KJ; Buxton AE; Peterson ED; Sanders GD
    J Cardiovasc Electrophysiol; 2010 Jul; 21(7):791-8. PubMed ID: 20132397
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Employment Status and Sick Leave After First-Time Implantable Cardioverter Defibrillator Implantation: Results From the COPE-ICD Trial.
    Christensen AV; Øhlers AA; Zwisler AD; Svendsen JH; Berg SK
    J Cardiovasc Nurs; 2017; 32(5):448-454. PubMed ID: 27631118
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Single-coil and dual-coil defibrillator leads and association with clinical outcomes in a complete Danish nationwide ICD cohort.
    Larsen JM; Hjortshøj SP; Nielsen JC; Johansen JB; Petersen HH; Haarbo J; Johansen MB; Thøgersen AM
    Heart Rhythm; 2016 Mar; 13(3):706-12. PubMed ID: 26593333
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The
    Kramer DB; Habtemariam D; Adjei-Poku Y; Samuel M; Engorn D; Reynolds MR; Mitchell SL
    J Am Heart Assoc; 2017 Sep; 6(9):. PubMed ID: 28939708
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cardioverter defibrillator implantation without induction of ventricular fibrillation: a single-blind, non-inferiority, randomised controlled trial (SIMPLE).
    Healey JS; Hohnloser SH; Glikson M; Neuzner J; Mabo P; Vinolas X; Kautzner J; O'Hara G; VanErven L; Gadler F; Pogue J; Appl U; Gilkerson J; Pochet T; Stein KM; Merkely B; Chrolavicius S; Meeks B; Foldesi C; Thibault B; Connolly SJ;
    Lancet; 2015 Feb; 385(9970):785-91. PubMed ID: 25715991
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Restrictions for ICD patients in daily life].
    Köbe J; Gradaus R; Zumhagen S; Böcker D
    Herz; 2005 Nov; 30(7):625-9. PubMed ID: 16333589
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy and safety of implantable cardioverter-defibrillators in patients with Chagas disease.
    Barbosa MP; da Costa Rocha MO; de Oliveira AB; Lombardi F; Ribeiro AL
    Europace; 2013 Jul; 15(7):957-62. PubMed ID: 23376978
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Shock and patient preimplantation type D personality are associated with poor health status in patients with implantable cardioverter-defibrillator.
    Pedersen SS; Tekle FB; Hoogwegt MT; Jordaens L; Theuns DA
    Circ Cardiovasc Qual Outcomes; 2012 May; 5(3):373-80. PubMed ID: 22570357
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Age and Outcomes of Primary Prevention Implantable Cardioverter-Defibrillators in Patients With Nonischemic Systolic Heart Failure.
    Elming MB; Nielsen JC; Haarbo J; Videbæk L; Korup E; Signorovitch J; Olesen LL; Hildebrandt P; Steffensen FH; Bruun NE; Eiskjær H; Brandes A; Thøgersen AM; Gustafsson F; Egstrup K; Videbæk R; Hassager C; Svendsen JH; Høfsten DE; Torp-Pedersen C; Pehrson S; Køber L; Thune JJ
    Circulation; 2017 Nov; 136(19):1772-1780. PubMed ID: 28877914
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.